DR. AVNER RAMU, M.D.
Osteopathic Medicine at Brompton St, Houston, TX
License number
Texas 0101028563
Category
Osteopathic Medicine
Type
General Practice
Address
Address
7541 Brompton St, Houston, TX 77025
Phone
(713) 666-6212
Personal information
See more information about AVNER RAMU at radaris.comName
Address
Phone
7541 Brompton St, Houston, TX 77025
Houston, TX
7541 Brompton St, Houston, TX 77025
Professional information
Methods Of Using Vesicant Drug Formulations
US Patent:
2001005, Dec 27, 2001
Filed:
Mar 9, 2001
Appl. No.:
09/803446
Inventors:
Avner Ramu - Houston TX, US
International Classification:
A61K031/704, A61K031/522, A61K031/4164
US Classification:
514/154000, 514/034000, 514/400000, 514/264000
Abstract:
The present invention relates to methods of treating, as well as preventing extravasation injury. In particular, the present invention pertains to photochemotherapeutic methods of prophylaxis and/or treatment of extravasation injury induced by vesicant antineoplastic drugs and other pharmaceutical formulations. In accordance with the present invention, extravasation injury is prevented or minimized by the coadministration of photoinactivation inducing compounds in a formulation comprising a vesicant antineoplastic or other pharmaceutical formulation, and subsequently exposing the injection or infusion site to photoexciting light.
Formulations Of Vesicant Drugs And Methods Of Use Thereof
US Patent:
5780446, Jul 14, 1998
Filed:
Jul 9, 1996
Appl. No.:
8/700742
Inventors:
Avner Ramu - Houston TX
Assignee:
Baylor College of Medicine - Houston TX
International Classification:
A61K 3170, A61K 31525
US Classification:
514 34
Abstract:
The present invention relates to methods of treating, as well as preventing extravasation injury. In particular, the present invention pertains to photochemotherapeutic methods of prophylaxis and/or treatment of extravasation injury induced by vesicant antineoplastic drugs and other pharmaceutical formulations. In accordance with the present invention, extravasation injury is prevented or minimized by the coadministration of photoinactivation inducing compounds in a formulation comprising a vesicant antineoplastic or other pharmaceutical formulation, and subsequently exposing the injection or infusion site to photoexciting light.